## Contents

### EDITORIAL

1. **Looking Forward to 2013—Saluting the Exceptional Year in 2012**  
   Scott M. Lippman

### PERSPECTIVE

4. **Enriching the Molecular Definition of the Airway "Field of Cancerization:" Establishing New Paradigms for the Patient at Risk for Lung Cancer**  
   Brigitte N. Gomperts, Tonya C. Walser, Avrum Spira, and Steven M. Dubinett  
   *See article, p. 8*

### RESEARCH ARTICLES

8. **Characterizing the Molecular Spatial and Temporal Field of Injury in Early-Stage Smoker Non–Small Cell Lung Cancer Patients after Definitive Surgery by Expression Profiling**  
   Humam Kadara, Li Shen, Junya Fujimoto, Pierre Saintigny, Chi-Wan Chow, Wenhua Lang, Zuoming Chu, Melinda Garcia, Mohamed Kabbout, You-Hong Fan, Carmen Behrens, Diane A. Liu, Li Mao, J. Jack Lee, Kathryn A. Gold, Jing Wang, Kevin R. Coombes, Edward S. Kim, Waun Ki Hong, and Ignacio I. Wistuba  
   *See commentary, p. 4*

18. **MUC1 Vaccine for Individuals with Advanced Adenoma of the Colon: A Cancer Immunoprevention Feasibility Study**  
   Takashi Kimura, John R. McKolanis, Lynda A. Dzubinski, Kazi Islam, Douglas M. Potter, Andres M. Salazar, Robert E. Schoen, and Olivera J. Finn

27. **Dietary Resveratrol Prevents Development of High-Grade Prostatic Intraepithelial Neoplastic Lesions: Involvement of SIRT1/S6K Axis**  
   Guiming Li, Paul Rivas, Roble Bedolla, Dinesh Thapa, Robert L. Reddick, Rita Ghosh, and Addanki P. Kumar

40. **Inositol Hexaphosphate Inhibits Tumor Growth, Vascularity, and Metabolism in TRAMP Mice: A Multiparametric Magnetic Resonance Study**  
   Komal Raina, Kameswaran Ravichandran, Subapriya Rajamanickam, Kendra M. Huber, Natalie J. Serkova, and Rajesh Agarwal

51. **A Feasibility Study of the Intraductal Administration of Chemotherapy**  
   Susan M. Love, Wei Zhang, Eva J. Gordon, Jianyu Rao, Hongying Yang, Junyao Li, Bailin Zhang, Xiang Wang, Guoji Chen, and Baoning Zhang

59. **Mapping of Three Genetic Determinants of Susceptibility to Estrogen-Induced Mammary Cancer within the Emca8 Locus on Rat Chromosome 5**  
   Beverly S. Schaffer, Kristin M. Leland-Wavrin, Scott G. Kurz, John A. Colletti, Nicole L. Seiler, Christopher L. Warren, and James D. Shull

### CORRECTION

70. **Correction: A Novel Sulindac Derivative that Potently Suppresses Colon Tumor Cell Growth by Inhibiting cGMP Phosphodiesterase and β-Catenin Transcriptional Activity**  
   **Correction:** A novel sulindac derivative that potently suppresses colon tumor cell growth by inhibiting cGMP phosphodiesterase and β-catenin transcriptional activity.
ABOUT THE COVER

Prostate cancer (PCa) is the most frequently diagnosed malignancy in elderly American men, though both incidence and associated mortality is lower in Asian compared to Western countries. Due to this difference in PCa incidence, inositol hexaphosphate (IP6), ubiquitously present in the Asian diet and a major constituent of high fiber content diets, has triggered interest for its possible chemopreventive effects in this disease. In this study, the dose-dependent effect of IP6 feeding on prostate sizes/volume and tumor vascularization (quantitatively imaged by gadolinium (Gd) uptake) was evaluated in prostate tumors of TRAMP mice. This noninvasive, in vivo imaging technique visualized the effect of IP6 on prostate tumorigenesis as a function of time. The cover shows representative DCE-MRI images of Gd uptake in prostate tumor of TRAMP mice (untreated control vs. 2% and 4% IP6-fed mice; not shown) up to 10 minutes post-Gd injection. The pseudocolor represents incremental signal intensity (blue representing highest Gd uptake) assessing tumor perfusion and permeability in prostate tumor. 2% IP6 dose was shown to exhibit significant antitumor efficacy and to suppress growth and progression of PCa via its ability to alter tumor vascularity (data/images not shown). These chemopreventive effects of IP6 against PCa could have translational potential in controlling the clinical progression of PCa in patients diagnosed at the early stage of the disease. See article by Raina et al. (beginning on page 40) for more information.